Literature DB >> 18765532

Postradiation sensitization of the histone deacetylase inhibitor valproic acid.

Prakash Chinnaiyan1, David Cerna, William E Burgan, Katie Beam, Eli S Williams, Kevin Camphausen, Philip J Tofilon.   

Abstract

PURPOSE: Preclinical studies evaluating histone deacetylase (HDAC) inhibitor-induced radiosensitization have largely focused on the preirradiation setting based on the assumption that enhanced radiosensitivity was mediated by changes in gene expression. Our previous investigations identified maximal radiosensitization when cells were exposed to HDAC inhibitors in both the preradiation and postradiation setting. We now expand on these studies to determine whether postirradiation exposure alone affects radiosensitivity. EXPERIMENTAL
DESIGN: The effects of the HDAC inhibitor valproic acid (VA) on postirradiation sensitivity in human glioma cell lines were evaluated using a clonogenic assay, exposing cells to VA up to 24 h after irradiation. DNA damage repair was evaluated using gammaH2AX and 53BP1 foci and cell cycle phase distribution was analyzed by flow cytometry. Western blot of acetylated gammaH2AX was done following histone extraction on AUT gels.
RESULTS: VA enhanced radiosensitivity when delivered up to 24 h after irradiation. Cells accumulated in G(2)-M following irradiation, although they returned to baseline at 24 h, mitigating the role of cell cycle redistribution in postirradiation sensitization by VA. At 12 h after irradiation, significant gammaH2AX and 53BP1 foci dispersal was shown in the control, although cells exposed to VA after irradiation maintained foci expression. VA alone had no effect on the acetylation or phosphorylation of H2AX, although it did acetylate radiation-induced gammaH2AX.
CONCLUSIONS: These results indicate that VA enhances radiosensitivity at times up to 24 h after irradiation, which has direct clinical application.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765532      PMCID: PMC3393085          DOI: 10.1158/1078-0432.CCR-08-0643

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  Pathways of DNA double-strand break repair during the mammalian cell cycle.

Authors:  Kai Rothkamm; Ines Krüger; Larry H Thompson; Markus Löbrich
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

2.  Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX.

Authors:  Irene M Ward; Kay Minn; Katherine G Jorda; Junjie Chen
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

3.  The cellular response to DNA double-strand breaks: defining the sensors and mediators.

Authors:  John H J Petrini; Travis H Stracker
Journal:  Trends Cell Biol       Date:  2003-09       Impact factor: 20.808

4.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

Authors:  Keith B Glaser; Michael J Staver; Jeffrey F Waring; Joshua Stender; Roger G Ulrich; Steven K Davidsen
Journal:  Mol Cancer Ther       Date:  2003-02       Impact factor: 6.261

5.  Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.

Authors:  Kevin Camphausen; David Cerna; Tamalee Scott; Mary Sproull; William E Burgan; Michael A Cerra; Howard Fine; Philip J Tofilon
Journal:  Int J Cancer       Date:  2005-04-10       Impact factor: 7.396

6.  p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice.

Authors:  Irene M Ward; Kay Minn; Jan van Deursen; Junjie Chen
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Histone acetylation-mediated regulation of genes in leukaemic cells.

Authors:  A E Chambers; S Banerjee; T Chaplin; J Dunne; S Debernardi; S P Joel; B D Young
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

Review 8.  Inhibition of histone deacetylation: a strategy for tumor radiosensitization.

Authors:  Kevin Camphausen; Philip J Tofilon
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

9.  Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

Authors:  Kevin Camphausen; William Burgan; Michael Cerra; Kelli A Oswald; Jane B Trepel; Min-Jung Lee; Philip J Tofilon
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

10.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Authors:  Constantine S Mitsiades; Nicholas S Mitsiades; Ciaran J McMullan; Vassiliki Poulaki; Reshma Shringarpure; Teru Hideshima; Masaharu Akiyama; Dharminder Chauhan; Nikhil Munshi; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  46 in total

Review 1.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

2.  Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.

Authors:  Emily Chan; Lori R Arlinghaus; Dana B Cardin; Laura Goff; Jordan D Berlin; Alexander Parikh; Richard G Abramson; Thomas E Yankeelov; Scott Hiebert; Nipun Merchant; Srividya Bhaskara; Anuradha Bapsi Chakravarthy
Journal:  Radiother Oncol       Date:  2016-04-19       Impact factor: 6.280

Review 3.  Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?

Authors:  Darren Hargrave
Journal:  CNS Oncol       Date:  2012-11

4.  Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.

Authors:  Krista A Van Nifterik; Jaap Van den Berg; Ben J Slotman; M Vincent M Lafleur; Peter Sminia; Lukas J A Stalpers
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

Review 5.  Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.

Authors:  Dayle Rundle-Thiele; Richard Head; Leah Cosgrove; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

6.  Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

Authors:  Caroline Happold; Thierry Gorlia; Olivier Chinot; Mark R Gilbert; L Burt Nabors; Wolfgang Wick; Stephanie L Pugh; Monika Hegi; Timothy Cloughesy; Patrick Roth; David A Reardon; James R Perry; Minesh P Mehta; Roger Stupp; Michael Weller
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

7.  HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells.

Authors:  Xufeng Chen; Patty Wong; Eric Radany; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

Review 8.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

9.  Valproic acid use during radiation therapy for glioblastoma associated with improved survival.

Authors:  Christopher A Barker; Andrew J Bishop; Maria Chang; Kathryn Beal; Timothy A Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-20       Impact factor: 7.038

Review 10.  Targeting of histone deacetylases in brain tumors.

Authors:  Jonas Ecker; Olaf Witt; Till Milde
Journal:  CNS Oncol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.